Creo Medical

UK-based Creo Medical focuses on the development and commercialisation of minimally invasive electrosurgical devices. Its six products in the flagship CROMA platform have all been CE marked, with five cleared by the FDA. Acquired in 2020, Albyn Medical provides Creo with profitable products and a direct salesforce in Europe.

Equities

Equities by Sector

Sectors

Megatrends

Thematics

Latest

Edison explains: Europe’s ageing buildings

Stock of the month – PZ Cussons

Q226 reflections: Leadership swings back – the value case holds

Audiovisual

Latest

The Metals Company – equity proposition

Vantage: Rockwood Strategic – UK small-cap value and active engagement

Bull, Bear & Beyond – Living REIT: executive interview

About Edison

Corporates

Investors

Careers

Creo Medical (AIM: CREO)

Latest News

Latest Insights

Creo Medical’s (LSE: CREO) H126 results build momentum

Creo Medical’s (LSE: CREO) Speedboat enters the UK private hospital market

Creo Medical — Leaner structure, sharper focus

Creo Medical — FY25 results validate growth strategy

Market Data

Sector

Equity Analyst

Key Management

Share Price Chart

Creo Medical — Intuitive deal expansion is a notable milestone

Creo Medical – executive interview with Craig Gulliford, CEO

Creo Medical — Setting the stage for pivotal growth

Creo Medical — NHS data validates Speedboat’s economic merit

Creo Medical — MicroBlate Flex progresses with first robotics use

Creo Medical — Solid FY23 lays the groundwork for 2024

Creo Medical — UltraSlim launch – kicking off FY24 momentum

Creo Medical — FDA nod for UltraSlim

Creo Medical — Potential UltraSlim upside with swift EU pathway

Creo Medical — Detailed half-yearly reflecting Speedboat traction

Creo Medical – executive interview with Craig Gulliford, CEO

Creo Medical — Growth momentum with core strength

Creo Medical — CE extension nearly doubles addressable GI

Creo Medical — NICE to review Speedboat Inject

Creo Medical — New NHS client win for CROMA technology

Creo Medical — Entering phase of accelerating growth inflection

Creo Medical — Albyn Medical stake acquired as wholly owned

Creo Medical — Observational studies to expand capabilities

Creo Medical — Around £30m raised in 48 hours to back growth plans

Creo Medical — Progressing on all fronts

Creo Medical — A rewarding FY22 for core technology arsenal

Creo Medical — Second robotics deal signed

Creo Medical — Building momentum in 2022

Creo Medical — Continued growth momentum in H122

Creo Medical — Solid FY21 followed by robotics deal with Intuitive

Creo Medical — Positive Q122 trading update

Creo — Unlocking the potential of rare cannabinoids

Edison Open House – Creo Medical

Creo Medical — Providing energy for endoscopic surgery